SCHEMBL4160760

SCHEMBL4160760

CCOC(=O)c1cc2c(Cl)ccc(-c3ccccc3C)c2[nH]1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 1/20 0.51
CCNB1 P14635 1/20 0.51
ALOX5 P09917 7/20 0.46
PTGES O14684 4/20 0.46
SMN1; SMN2 Q16637 3/20 0.45
ALDH1A1 P00352 3/20 0.45
HPGD P15428 3/20 0.45
MEN1 O00255 2/20 0.45
MAPT P10636 2/20 0.45
KMT2A Q03164 2/20 0.45
KDM4E B2RXH2 2/20 0.45
RAB9A P51151 2/20 0.45
GAA P10253 2/20 0.45
NPC1 O15118 1/20 0.45
LMNA P02545 1/20 0.45
GLA P06280 1/20 0.45
ATM Q13315 1/20 0.45
ALOX15 P16050 1/20 0.44
KDR P35968 1/20 0.43
TP53 P04637 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8318032 0.84 CDK1 (0.54) CDK1CCNB1ALOX5PTGESSMN1; SMN2
SCHEMBL8325034 0.84 CDK1 (0.63) CDK1CCNB1ALOX5PTGESSMN1; SMN2
SCHEMBL4167884 0.80 ALOX5 (0.41) CDK1CCNB1ALOX5PTGESSMN1; SMN2
SCHEMBL5357191 0.80 CDK1 (0.52) CDK1CCNB1ALOX5PTGESSMN1; SMN2
SCHEMBL7658260 0.80 CDK1 (0.52) CDK1CCNB1ALOX5PTGESSMN1; SMN2
SCHEMBL4168669 0.80 RAB9A (0.59) CDK1CCNB1ALOX5PTGESSMN1; SMN2
SCHEMBL4174868 0.80 CDK1 (0.52) CDK1CCNB1ALOX5PTGESSMN1; SMN2
SCHEMBL7877547 0.77 CDK1 (0.47) CDK1CCNB1SMN1; SMN2ALDH1A1HPGD
SCHEMBL7665395 0.76 FBP1 (0.53) CDK1CCNB1ALDH1A1MEN1MAPT
SCHEMBL22042078 0.74 CDK1 (0.58) CDK1CCNB1ALOX5PTGESSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3243814-B1 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS ABBVIE INC (US) 2018-10-17 EP disclosed
EP-3243814-A1 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS AbbVie Inc. (US) 2017-11-15 EP disclosed
EP-2134684-B1 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS ABBVIE INC (US) 2017-08-02 EP disclosed
US-9359296-B2 7-substituted indole Mcl-1 inhibitors ABBVIE INC. (US) 2016-06-07 US disclosed
US-20150284328-A1 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS ABBVIE INC (US) 2015-10-08 US disclosed
US-9035047-B2 7-substituted indole Mcl-1 inhibitors ABBVIE INC. (US) 2015-05-19 US disclosed
US-20140051683-A1 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS ABBVIE INC. (US) 2014-02-20 US disclosed
US-8445679-B2 7-substituted indole MCL-1 inhibitors ABBVIE INC. (US) 2013-05-21 US disclosed
EP-2134684-A2 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS Abbott Laboratories (US) 2009-12-23 EP disclosed
US-20090054402-A1 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS ABBOTT LABORATORIES (US) 2009-02-26 US disclosed
WO-2008131000-A2 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS ABBOTT LABORATORIES (US) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140051683-A1 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS MCL1, BCL2L1, API5 CDK1 371/4885CCNB1 1052/4885ALOX5 3867/4885
US-20150284328-A1 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS MCL1, BCL2L1, API5 CDK1 371/4885CCNB1 1052/4885ALOX5 3867/4885
US-20090054402-A1 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS MCL1, BCL2L1, API5 CDK1 371/4885CCNB1 1052/4885ALOX5 3867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.